In 1,503 patients with STEMI undergoing primary PCI, adjunctive intravenous nicorandil did not reduce 12-month CV death, MI, target vessel revascularisation or heart failure hospitalisation vs placebo (13.1% vs 13.1%; rate ratio 0.869, 95% CI 0.650-1.162).
RCTn = 1,503
Huang et al. Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI: The CLEAN Randomized Clinical Trial